Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-7.